The Role of Positron Emission Tomography in Selecting Patients with Metastatic Cancer for Adrenalectomy
- 1 May 2000
- journal article
- Published by SAGE Publications in The American Surgeon
- Vol. 66 (5) , 432-437
- https://doi.org/10.1177/000313480006600503
Abstract
Metastases to the adrenal glands usually signal disseminated disease. However, isolated metastases do occur that may be curable with adrenalectomy. Functional imaging with positron emission tomography (PET) can differentiate benign from malignant pathology and isolated from disseminated metastases. The purpose of this study was to determine whether PET scanning can influence the outcome of adrenalectomy for metastatic disease. We conducted a retrospective review of eight patients undergoing adrenalectomy for presumed isolated metastatic disease from 1985 through 1997. The patients included six women and two men with an average age of 58 (range, 36–74). Their primary tumors were six lung carcinomas, one renal cell carcinoma, and one colon carcinoma. The adrenal masses were located on the right in six patients, on the left in one, and bilaterally in one. Before operation, all patients were evaluated by chest and abdominal CT. Four patients were also evaluated by PET scan. Six right, one left, and one bilateral adrenalectomies were performed. Associated organ resections included two right partial nephrectomies and one right total nephrectomy, one left partial nephrectomy, two distal pancreatectomies, one splenectomy, and two partial hepatic resections. All eight patients survived operation. There were no major perioperative complications, but one patient required readmission for congestive heart failure. Three of the four patients who did not have PET scanning died from 4 to 48 months after operation with disseminated disease from lung, colon, and renal carcinoma respectively. The remaining patient who did not have PET scanning is alive and well 11 years later. Two of the four patients who had PET scans showing isolated disease are alive at 28 and 43 months after operation, whereas the other two died of disseminated disease at 29 and 36 months after operation. We conclude that 1) adrenalectomy can provide survival benefit in patients with isolated metastases, and 2) PET scanning is useful in confirming isolated metastatic disease and selecting patients for adrenalectomy.Keywords
This publication has 12 references indexed in Scilit:
- Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.American Journal of Roentgenology, 1997
- Does Resection of Adrenal Metastases From Non-Small Cell Lung Cancer Improve Survival?The Annals of Thoracic Surgery, 1996
- Successful treatment of solitary extracranial metastases from non—small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.Radiology, 1995
- Operative management of adrenal metastases from lung carcinomaUrology, 1993
- Hanson lecture. Adrenal imaging: current status.American Journal of Roentgenology, 1990
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- Management of nonsmall cell lung carcinoma with solitary brain metastasisThe Journal of Thoracic and Cardiovascular Surgery, 1989
- Serendipitous adrenal masses: Prevalence, significance, and managementThe American Journal of Surgery, 1985
- Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma.Radiology, 1984